ALNY logo

Alnylam Pharmaceuticals, Inc. (ALNY) Cash From Operations

Annual CFO:

-$8.31M-$112.47M(-107.98%)
December 31, 2024

Summary

  • As of today, ALNY annual cash from operations is -$8.31 million, with the most recent change of -$112.47 million (-107.98%) on December 31, 2024.
  • During the last 3 years, ALNY annual cash from operations has risen by +$633.38 million (+98.70%).
  • ALNY annual cash from operations is now -104.23% below its all-time high of $196.52 million, reached on December 31, 2007.

Performance

ALNY Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherALNYcash flow metrics

Quarterly CFO:

$153.73M+$272.04M(+229.93%)
June 30, 2025

Summary

  • As of today, ALNY quarterly cash from operations is $153.73 million, with the most recent change of +$272.04 million (+229.93%) on June 30, 2025.
  • Over the past year, ALNY quarterly cash from operations has increased by +$29.57 million (+23.82%).
  • ALNY quarterly cash from operations is now -57.23% below its all-time high of $359.41 million, reached on September 30, 2023.

Performance

ALNY Quarterly Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherALNYcash flow metrics

TTM CFO:

-$15.54M+$29.57M(+65.55%)
June 30, 2025

Summary

  • As of today, ALNY TTM cash from operations is -$15.54 million, with the most recent change of +$29.57 million (+65.55%) on June 30, 2025.
  • Over the past year, ALNY TTM cash from operations has dropped by -$387.80 million (-104.17%).
  • ALNY TTM cash from operations is now -104.17% below its all-time high of $372.26 million, reached on June 30, 2024.

Performance

ALNY TTM Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherALNYcash flow metrics

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

ALNY Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year-108.0%+23.8%-104.2%
3Y3 Years+98.7%+225.2%+97.3%
5Y5 Years+97.0%+213.6%+97.7%

ALNY Cash From Operations Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-108.0%+98.7%-57.2%+192.3%-104.2%+97.2%
5Y5-Year-108.0%+98.7%-57.2%+165.2%-104.2%+97.7%
All-TimeAll-Time-104.2%+98.7%-57.2%+162.4%-104.2%+98.0%

ALNY Cash From Operations History

DateAnnualQuarterlyTTM
Jun 2025
-
$153.73M(+229.9%)
-$15.54M(+65.6%)
Mar 2025
-
-$118.31M(-25.0%)
-$45.11M(-442.7%)
Dec 2024
-$8.31M(-108.0%)
-$94.66M(-316.6%)
-$8.31M(-114.7%)
Sep 2024
-
$43.71M(-64.8%)
$56.55M(-84.8%)
Jun 2024
-
$124.16M(+252.3%)
$372.26M(+96.8%)
Mar 2024
-
-$81.52M(-173.6%)
$189.12M(+81.6%)
Dec 2023
$104.16M(+119.2%)
-$29.80M(-108.3%)
$104.16M(+5179.1%)
Sep 2023
-
$359.41M(+709.3%)
$1.97M(+100.4%)
Jun 2023
-
-$58.99M(+64.6%)
-$472.72M(+11.9%)
Mar 2023
-
-$166.47M(-26.1%)
-$536.56M(+0.9%)
Dec 2022
-$541.27M(+15.6%)
-$131.98M(-14.5%)
-$541.27M(+3.2%)
Sep 2022
-
-$115.28M(+6.1%)
-$559.44M(+3.2%)
Jun 2022
-
-$122.82M(+28.3%)
-$578.19M(-0.2%)
Mar 2022
-
-$171.19M(-14.0%)
-$577.23M(+10.0%)
Dec 2021
-$641.69M(-4.3%)
-$150.14M(-12.0%)
-$641.69M(-4.4%)
Sep 2021
-
-$134.04M(-10.0%)
-$614.70M(-4.0%)
Jun 2021
-
-$121.86M(+48.3%)
-$590.99M(+2.2%)
Mar 2021
-
-$235.66M(-91.4%)
-$604.46M(+1.7%)
Dec 2020
-$614.96M(-120.9%)
-$123.14M(-11.6%)
-$614.96M(+10.6%)
Sep 2020
-
-$110.33M(+18.5%)
-$687.80M(+9.5%)
Jun 2020
-
-$135.33M(+45.0%)
-$760.10M(-126.2%)
Mar 2020
-
-$246.16M(-25.6%)
-$336.08M(-20.7%)
Dec 2019
-$278.43M(+50.5%)
-$195.98M(-7.3%)
-$278.43M(-19.5%)
Sep 2019
-
-$182.63M(-163.3%)
-$232.90M(-14.1%)
Jun 2019
-
$288.69M(+253.1%)
-$204.08M(+65.7%)
Mar 2019
-
-$188.51M(-25.3%)
-$595.46M(-5.8%)
Dec 2018
-$562.62M(-47.0%)
-$150.46M(+2.2%)
-$562.62M(-9.2%)
Sep 2018
-
-$153.81M(-49.8%)
-$515.20M(-12.1%)
Jun 2018
-
-$102.69M(+34.0%)
-$459.76M(-4.9%)
Mar 2018
-
-$155.66M(-51.1%)
-$438.12M(-14.5%)
Dec 2017
-$382.79M(-24.4%)
-$103.04M(-4.8%)
-$382.79M(-6.9%)
Sep 2017
-
-$98.36M(-21.4%)
-$358.08M(-6.8%)
Jun 2017
-
-$81.05M(+19.2%)
-$335.25M(-3.3%)
Mar 2017
-
-$100.33M(-28.1%)
-$324.41M(-5.4%)
Dec 2016
-$307.70M(-62.7%)
-$78.34M(-3.7%)
-$307.70M(-8.9%)
Sep 2016
-
-$75.54M(-7.6%)
-$282.43M(-8.1%)
Jun 2016
-
-$70.20M(+16.0%)
-$261.26M(-6.0%)
Mar 2016
-
-$83.62M(-57.6%)
-$246.51M(-30.3%)
Dec 2015
-$189.14M(-14.2%)
-$53.06M(+2.4%)
-$189.14M(-9.5%)
Sep 2015
-
-$54.37M(+2.0%)
-$172.71M(-8.6%)
Jun 2015
-
-$55.46M(-111.2%)
-$159.05M(-5.9%)
Mar 2015
-
-$26.25M(+28.3%)
-$150.22M(+9.3%)
Dec 2014
-$165.64M
-$36.63M(+10.0%)
-$165.64M(-9.4%)
Sep 2014
-
-$40.71M(+12.7%)
-$151.38M(-14.3%)
DateAnnualQuarterlyTTM
Jun 2014
-
-$46.63M(-11.9%)
-$132.38M(-21.1%)
Mar 2014
-
-$41.67M(-86.3%)
-$109.36M(-59.3%)
Dec 2013
-$68.66M(+40.6%)
-$22.37M(-3.0%)
-$68.66M(+40.4%)
Sep 2013
-
-$21.71M(+8.0%)
-$115.20M(-30.5%)
Jun 2013
-
-$23.60M(-2330.7%)
-$88.27M(-2.2%)
Mar 2013
-
-$971.00K(+98.6%)
-$86.36M(+25.3%)
Dec 2012
-$115.61M(-32.8%)
-$68.91M(-1422.2%)
-$115.61M(-60.9%)
Sep 2012
-
$5.21M(+124.0%)
-$71.86M(+32.3%)
Jun 2012
-
-$21.69M(+28.2%)
-$106.09M(+4.4%)
Mar 2012
-
-$30.21M(-20.1%)
-$110.98M(-27.5%)
Dec 2011
-$87.07M(-3.2%)
-$25.16M(+13.3%)
-$87.07M(-5.8%)
Sep 2011
-
-$29.02M(-9.2%)
-$82.30M(-6.5%)
Jun 2011
-
-$26.58M(-321.6%)
-$77.31M(-3.0%)
Mar 2011
-
-$6.30M(+69.1%)
-$75.05M(+11.0%)
Dec 2010
-$84.34M(-16.9%)
-$20.39M(+15.2%)
-$84.34M(-4.4%)
Sep 2010
-
-$24.04M(+1.1%)
-$80.82M(-4.5%)
Jun 2010
-
-$24.31M(-55.8%)
-$77.37M(+13.0%)
Mar 2010
-
-$15.60M(+7.5%)
-$88.98M(-23.3%)
Dec 2009
-$72.14M(-210.2%)
-$16.87M(+18.1%)
-$72.14M(-20.0%)
Sep 2009
-
-$20.59M(+42.7%)
-$60.13M(-8.2%)
Jun 2009
-
-$35.92M(-3017.9%)
-$55.55M(-173.7%)
Mar 2009
-
$1.23M(+125.4%)
$75.38M(+15.1%)
Dec 2008
$65.49M(-66.7%)
-$4.85M(+69.7%)
$65.49M(+5.8%)
Sep 2008
-
-$16.01M(-116.9%)
$61.90M(-79.5%)
Jun 2008
-
$95.01M(+1197.3%)
$302.22M(+52.0%)
Mar 2008
-
-$8.66M(-2.6%)
$198.82M(+1.2%)
Dec 2007
$196.52M(+897.9%)
-$8.44M(-103.8%)
$196.52M(-1.9%)
Sep 2007
-
$224.31M(+2773.2%)
$200.34M(+844.9%)
Jun 2007
-
-$8.39M(+23.4%)
-$26.90M(-0.0%)
Mar 2007
-
-$10.96M(-137.6%)
-$26.89M(-9.2%)
Dec 2006
-$24.63M(-49.4%)
-$4.61M(-57.3%)
-$24.63M(-50.2%)
Sep 2006
-
-$2.93M(+65.0%)
-$16.40M(+16.7%)
Jun 2006
-
-$8.38M(+3.7%)
-$19.68M(-12.1%)
Mar 2006
-
-$8.70M(-340.7%)
-$17.55M(-6.5%)
Dec 2005
-$16.48M(+15.8%)
$3.62M(+158.2%)
-$16.48M(+21.9%)
Sep 2005
-
-$6.21M(+0.6%)
-$21.12M(-14.0%)
Jun 2005
-
-$6.25M(+18.2%)
-$18.52M(+1.1%)
Mar 2005
-
-$7.64M(-651.9%)
-$18.71M(+4.4%)
Dec 2004
-$19.57M(-52.6%)
-$1.02M(+71.9%)
-$19.57M(-5.5%)
Sep 2004
-
-$3.61M(+44.0%)
-$18.55M(-24.2%)
Jun 2004
-
-$6.45M(+24.1%)
-$14.94M(-75.9%)
Mar 2004
-
-$8.49M
-$8.49M
Dec 2003
-$12.83M(-903.8%)
-
-
Dec 2002
-$1.28M
-
-

FAQ

  • What is Alnylam Pharmaceuticals, Inc. annual cash from operations?
  • What is the all-time high annual cash from operations for Alnylam Pharmaceuticals, Inc.?
  • What is Alnylam Pharmaceuticals, Inc. annual cash from operations year-on-year change?
  • What is Alnylam Pharmaceuticals, Inc. quarterly cash from operations?
  • What is the all-time high quarterly cash from operations for Alnylam Pharmaceuticals, Inc.?
  • What is Alnylam Pharmaceuticals, Inc. quarterly cash from operations year-on-year change?
  • What is Alnylam Pharmaceuticals, Inc. TTM cash from operations?
  • What is the all-time high TTM cash from operations for Alnylam Pharmaceuticals, Inc.?
  • What is Alnylam Pharmaceuticals, Inc. TTM cash from operations year-on-year change?

What is Alnylam Pharmaceuticals, Inc. annual cash from operations?

The current annual cash from operations of ALNY is -$8.31M

What is the all-time high annual cash from operations for Alnylam Pharmaceuticals, Inc.?

Alnylam Pharmaceuticals, Inc. all-time high annual cash from operations is $196.52M

What is Alnylam Pharmaceuticals, Inc. annual cash from operations year-on-year change?

Over the past year, ALNY annual cash from operations has changed by -$112.47M (-107.98%)

What is Alnylam Pharmaceuticals, Inc. quarterly cash from operations?

The current quarterly cash from operations of ALNY is $153.73M

What is the all-time high quarterly cash from operations for Alnylam Pharmaceuticals, Inc.?

Alnylam Pharmaceuticals, Inc. all-time high quarterly cash from operations is $359.41M

What is Alnylam Pharmaceuticals, Inc. quarterly cash from operations year-on-year change?

Over the past year, ALNY quarterly cash from operations has changed by +$29.57M (+23.82%)

What is Alnylam Pharmaceuticals, Inc. TTM cash from operations?

The current TTM cash from operations of ALNY is -$15.54M

What is the all-time high TTM cash from operations for Alnylam Pharmaceuticals, Inc.?

Alnylam Pharmaceuticals, Inc. all-time high TTM cash from operations is $372.26M

What is Alnylam Pharmaceuticals, Inc. TTM cash from operations year-on-year change?

Over the past year, ALNY TTM cash from operations has changed by -$387.80M (-104.17%)
On this page